At Kiniksa, we put patients at the center of everything we do. Our goal is to advance therapies for patients suffering from debilitating immunological diseases with significant unmet medical need. We are also committed to understanding and supporting the broader needs of the patient communities. Hear Nadine's story of living with recurrent pericarditis.
Kiniksa was founded in 2015 and has developed into a fully-integrated biopharmaceutical company. Our management team and employees are focused on advancing a portfolio of immune-modulating, clinical-stage product candidates that target underserved conditions and offer the potential for differentiation.
Develop and commercialize a pipeline of product candidates with validated mechanisms of action, strong biologic rationale, and offer the potential for differentiation.
We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.